Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Betahistine

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Nov 30, 2027 · 460 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Betahistin (ATC-Code nach WHO: N07CA01)

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Betahistine (ATC code N07CA01).
  • Open-house participation model with contract conclusion available to all interested and eligible pharmaceutical companies during the participation period.
Pokaż pełne podsumowanie

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Betahistine (ATC N07CA01) with AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No contract value is stated, minimum purchase volumes are not guaranteed, and no individual negotiations or exclusivity apply. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Ryzyka

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical companies for the offered medicines.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Betahistine

Non-exclusive pharmaceutical rebate agreement for medicines containing Betahistine (ATC N07CA01). The lot is described as an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volumes are stated. Performance/place of use is Germany, specifically Dresden in Saxony, according to the structured data.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jan 2026 - Nov 2027

Kategoria

Pharmaceutical products

Termin

Deadline Nov 30, 2027

Szczegóły zamówienia

Data publikacji
23 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
778877-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3